Diagnostics: Page 18
-
Puerto Rico-based lab ceases COVID-19 test; FDA revokes EUA
The FDA disclosed the action alongside updates to the instructions for use for Thermo Fisher Scientific’s TaqPath COVID-19 test.
By Nick Paul Taylor • Sept. 26, 2022 -
Forget oximeters, smartphone cameras detect 79% of cases of low blood oxygen in small study
If the results are validated by wider studies, physicians will have a new tool to increase the number of people who can be monitored for chronic and acute respiratory conditions.
By Nick Paul Taylor • Sept. 23, 2022 -
Trendline
Medical device industry continues to turn to AI
While the industry continues to embrace artificial intelligence, there are still questions about how the new technologies need to be regulated and if they are effective.
By MedTech Dive staff -
Watchdog faults FDA for rushing COVID-19 tests to market by easing emergency use rules
HHS’ Office of Inspector General found that by loosening emergency use authorization requirements to bring COVID-19 tests to market faster, the agency allowed inaccurate tests to be distributed.
By Elise Reuter • Sept. 21, 2022 -
Racial bias in pulse oximeters to be subject of FDA panel
The design of the ubiquitous fingertip monitors has inadvertently caused false blood oxygen readings in darker-skinned patients, a problem the FDA hopes to fix.
By Peter Green • Sept. 16, 2022 -
FDA eases authorization policy for monkeypox tests as lab group points to ‘lessons learned’ from Covid-19
Laboratory group says new agency guidance that offers templates and more time to submit data should help test developers.
By Elise Reuter • Sept. 15, 2022 -
Medtech firms increasingly positive about future as staffing, inflation pressures ease, say RBC analysts
Hospital staffing and supply chain issues are expected to improve, according to comments from Boston Scientific, J&J, Medtronic, and others.
By Nick Paul Taylor • Sept. 15, 2022 -
Amid merger turmoil, Illumina’s Grail unit reports downturn in accuracy of blood-based cancer test
New data on Grail’s cancer screening test could weaken the company’s competitive standing against rivals Guardant Health, Exact Sciences and Freenome.
By Nick Paul Taylor • Sept. 12, 2022 -
Q&A
Friday Q&A: BD Life Sciences President Dave Hickey shares plans for expanded testing ‘menu’
Demand for COVID-19 tests may be slowing, but more laboratories have installed testing systems during the pandemic, the executive says.
By Elise Reuter • Sept. 8, 2022 -
FDA issues first EUA for monkeypox test
Quest Diagnostics' PCR test for monkeypox received emergency use authorization after the FDA issued guidance on how it will evaluate the tests.
By Elise Reuter • Sept. 8, 2022 -
HHS will allow EUAs for monkeypox tests to increase access in the US
The move follows the declaration of a public health emergency for the monkeypox outbreak on Aug. 4.
By Ricky Zipp • Sept. 7, 2022 -
Illumina’s hold on Grail depends now on separate appeals in US, Europe
Even as it plans to appeal a European Commission decision and the FTC plans to appeal a U.S. ruling, Illumina say it’s preparing for ‘strategic alternatives’ to its acquisition of early cancer detection firm Grail.
By Elise Reuter • Updated Sept. 7, 2022 -
Federal jury convicts medtech executive in $77M blood testing kickback case
Arrayit President Mark Schena’s conviction on nine federal charges carries a maximum sentence of more than 100 years in prison.
By Nick Paul Taylor • Sept. 6, 2022 -
Machine learning algorithm predicts unfavorable labor outcomes for mothers in retrospective study
The researchers plan to validate the model using Mayo Clinic patients before deploying it prospectively in maternity wards.
By Nick Paul Taylor • Sept. 6, 2022 -
Another COVID-19 test supplier ordered by FDA to take its products off the market
USA Medical has been warned by FDA that its rapid antigen tests had not been cleared or authorized by the agency.
By Elise Reuter • Sept. 1, 2022 -
Dispute over monkeypox test reimbursement rates may hurt effort to halt disease’s spread: experts
The CMS says regional administrators can set prices, even as lab group warns fees are too low for commercial firms to conduct testing.
By Elise Reuter • Aug. 31, 2022 -
Illumina opens first manufacturing facility in China to supply gene sequencing products
The company aims to produce all gene sequencing instruments and consumables locally within five years in a bid to expand its presence in the growing Chinese market.
By Nick Paul Taylor • Aug. 31, 2022 -
Olympus to sell microscope unit for $3.1B as it bolsters focus on medical technology
Bain Capital has taken the other side of the deal, paying $3.1 billion for a business it said is “at the frontier of digital optical technology in life sciences and industrial end markets.”
By Nick Paul Taylor • Aug. 30, 2022 -
Labcorp adds to hospital lab buying streak with New Jersey acquisition
The purchase comes as hospitals work to trim costs and testing firms seek stable revenue streams as COVID-19 testing winds down.
By Peter Green , Rebecca Pifer • Aug. 25, 2022 -
Lab group ACLA warns ‘inadequate’ payment rates may limit access to monkeypox testing
The trade group urged the CMS to ensure monkeypox testing claims are paid at its “reasonably derived” recommended rate to ensure access to testing.
By Nick Paul Taylor • Aug. 23, 2022 -
Abbott blood test predicts death, unfavorable outcomes in traumatic brain injury patients, study finds
Abbott is pursuing FDA clearance for the breakthrough-designated TBI test to expand access to a diagnostic that predicted death and severe disability.
By Nick Paul Taylor • Aug. 12, 2022 -
As monkeypox cases increase, disease experts lament lack of testing access
“It’s the same problem that happened with COVID-19. This is exactly identical,” said Amesh Adalja, a senior scholar at the Johns Hopkins Center for Health Security in Baltimore.
By Elise Reuter • Aug. 10, 2022 -
Roundup: Medical device industry confident it can ride out recession, wary of slowing capital sales
While companies may weather a recession, they still face challenges like hospital staffing shortages, supply chain disruption and inflation, RBC Capital Markets analysts wrote.
By Nick Paul Taylor • Updated Aug. 10, 2022 -
Senate passes $740B bill to lower healthcare costs after months of wrangling
While Republicans successfully challenged a planned $35 insulin price ceiling for patients on private insurance, the law still has implications for makers of diabetes devices.
By Nick Paul Taylor • Aug. 8, 2022 -
FDA’s breakthrough device designations poised for another record year
At the midpoint of the year, the FDA had granted 129 designations, suggesting it will break the previous full-year record of 206.
By Nick Paul Taylor • Aug. 8, 2022 -
QuidelOrtho reports 37.5% sales growth in first quarter since $6B merger
The testing firm is increasing sales after Quidel merged with Ortho, opening opportunities to cut costs and increase point-of-care and molecular diagnostics revenue.
By Nick Paul Taylor • Aug. 5, 2022